No CrossRef data available.
A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UK
Published online by Cambridge University Press: 17 January 2023
Abstract
Background
Adherence to preventative inhaled therapies in people with cystic fibrosis (CF) is low, resulting in potentially avoidable health losses and the need for costly rescue therapies.
Objectives
To estimate the cost-effectiveness of the CFHealthHub (CFHH) intervention to support adherence to inhaled medications.
Methods
A state transition model was developed to assess the cost-effectiveness of the CFHH intervention versus usual care from the perspective of the UK National Health Service and Personal Social Services over a lifetime horizon. Costs and health outcomes were discounted at a rate of 3.5 percent per annum. Costs were valued at 2021/22 prices. The model structure includes health states defined by survival status, level of lung function, and transplant history. Treatment effects were modeled by changing the probabilities of transitioning between lung function states and reducing exacerbation rates. Model parameters were informed by the CFHH trial, CF Registry data, routine cost databases, literature, and expert opinion. Deterministic and probabilistic sensitivity analyses were undertaken to assess uncertainty.
Results
The CFHH intervention is expected to generate additional health gains and cost savings compared with usual care. Assuming that it is delivered for 10 years, the CFHH intervention is expected to generate 0.17 additional quality-adjusted life years and cost savings of GBP 1,600 (EUR 1,662) per patient.
Conclusions
The CFHH intervention is expected to dominate usual care, irrespective of the duration over which the intervention is delivered. The modeled benefits and cost savings are smaller than initially expected and are sensitive to relative treatment effects on lung function.
- Type
- Assessment
- Information
- Copyright
- © University of Sheffield, 2023. Published by Cambridge University Press
References
Cystic Fibrosis Trust. UK cystic fibrosis registry 2021 annual data report. London: CF Trust; 2022.Google Scholar
Davies, JC, Alton, EW, Bush, A. Cystic fibrosis. BMJ. 2007;335:1255–1259.CrossRefGoogle ScholarPubMed
Emerson, J, Rosenfeld, M, McNamara, S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91–100.CrossRefGoogle ScholarPubMed
Mohindru, B, Turner, D, Sach, T, et al. Health state utility data in cystic fibrosis: A systematic review. Pharmacoeconomics. 2020;4:13–25.CrossRefGoogle ScholarPubMed
Döring, G, Flume, P, Heijerman, H, et al. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros. 2012;11:461–479.CrossRefGoogle ScholarPubMed
Quittner, AL, Zhang, J, Marynchenko, M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146:142–151.CrossRefGoogle ScholarPubMed
Daniels, T, Goodacre, L, Sutton, C, et al. Accurate assessment of adherence: Self-report and clinician report vs electronic monitoring of nebulizers. Chest. 2011;140:425–432.CrossRefGoogle ScholarPubMed
Hoo, ZH, Curley, R, Walters, SJ, et al. Exploring the implications of different approaches to estimate centre-level adherence using objective adherence data in an adult cystic fibrosis centre – A retrospective observational study. J Cyst Fibros. 2019;19:162–167.CrossRefGoogle Scholar
Eakin, MN, Bilderback, A, Boyle, MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10:258–264.CrossRefGoogle ScholarPubMed
Briesacher, BA, Quittner, AL, Saiman, L, et al. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm. Med. 2011;11, 5.CrossRefGoogle ScholarPubMed
Wildman, MJ, O’Cathain, A, Hind, D, et al. Development and evaluation of an intervention to support adherence to treatment in adults with Cystic Fibrosis: The ACtiF Research Programme. In: Programme grants for applied research. Southampton: NIHR; 2021. p. 1–180.Google Scholar
Wildman, MJ, O’Cathain, A, Maguire, C, et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: A randomised controlled trial. Thorax. 2022;77:461–469.CrossRefGoogle ScholarPubMed
Ratjen, F, Durham, T, Navratil, T, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros. 2012;11:539–549.CrossRefGoogle ScholarPubMed
Tappenden, P, Harnan, S, Uttley, L, et al. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: Systematic review and economic model. Health Technol Assess. 2013;17:1–181.CrossRefGoogle ScholarPubMed
Tappenden, P, Sadler, S, Wildman, M. An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. Pharmacoeconomics. 2017;35:647–659.CrossRefGoogle ScholarPubMed
Wildman, M. ACtiF trial data [data held on file]. Sheffield: University of Sheffield; 2019.Google Scholar
Cystic Fibrosis Trust. UK cystic fibrosis registry annual data report 2019. London: CF Trust; 2020.Google Scholar
Cystic Fibrosis Trust. CF registry bespoke dataset (years 2006–2015; data held on file). London: CF Trust; 2019.Google Scholar
Jones, KC, Burns, A. Unit costs of health and social care 2021. Kent: Personal Social Services Research Unit; 2021.Google Scholar
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press; 2022.Google Scholar
Anyanwu, A, McGuire, A, Rogers, C, et al. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax. 2001;56:218–222.CrossRefGoogle ScholarPubMed
Ara, R, Brazier, JE. Populating an economic model with health state utility values: Moving toward better practice. Value Health 2010;13:509–518.CrossRefGoogle ScholarPubMed
Keogh, RH, Szczesniak, R, Taylor-Robinson, D, et al. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros. 2018;17:218–227.CrossRefGoogle ScholarPubMed
Jackson, C. Multi-state models for panel data: The msm package for R. J Stat Softw. 2011;38:1–28.CrossRefGoogle Scholar
van Hout, B, Janssen, MF, Feng, YS, et al. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708–715.CrossRefGoogle ScholarPubMed
Hernández Alava, M, Wailoo, AJ. Fitting adjusted limited dependent variable mixture models to EQ-5D. Stata J. 2015;15:737–750.CrossRefGoogle Scholar
Hernández Alava, M, Wailoo, AJ, Ara, R. Tails from the peak district: Adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15:550–561.CrossRefGoogle ScholarPubMed
Bradley, JM, Blume, SW, Balp, MM, et al. Quality of life and healthcare utilisation in cystic fibrosis: A multicentre study. Eur Respir J. 2013;41:571–577.CrossRefGoogle ScholarPubMed
Weinstein, MC, O’Brien, B, Hornberger, J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices - Modeling studies. Value Health. 2003;6:9–17.CrossRefGoogle ScholarPubMed
Drummond, MF, Sculpher, MJ, Claxton, K, et al. Methods for the economic evaluation of health care programmes. 4th ed. New York: Oxford University Press; 2015.Google Scholar
Mohindru, B, Turner, D, Sach, T, et al. Health economic modelling in cystic fibrosis: A systematic review. J Cyst Fibros. 2019;18:452–460.CrossRefGoogle ScholarPubMed
Whiting, P, Al, M, Burgers, L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: A systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18:1–106.CrossRefGoogle ScholarPubMed
Vertex Pharmaceuticals. Cystic fibrosis (F508del mutation) - lumacaftor (with ivacaftor) [ID786]. London: Company’s Evidence Submission to the National Institute for Health and Care Excellence; 2015.Google Scholar
Bevan, A, Hoo, ZH, Totton, N, et al. Using a learning health system to understand the mismatch between medicines supply and actual medicines use among adults with cystic fibrosis. J Cyst Fibros. 2021;21:323–331.CrossRefGoogle ScholarPubMed
Tappenden et al. supplementary material
Tappenden et al. supplementary material
File
171.9 KB